BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25765597)

  • 1. Lurasidone for schizophrenia.
    Drug Ther Bull; 2015 Mar; 53(3):30-2. PubMed ID: 25765597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Honciuc M; Llorca PM
    Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
    Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
    Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
    Macaluso M; Kazanchi H; Preskorn SH
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
    Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
    Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
    Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
    Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurasidone in schizophrenia: new information about dosage and place in therapy.
    Citrome L
    Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
    Jaeschke RR; Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Styczeń K; Datka W
    Pharmacol Rep; 2016 Aug; 68(4):748-55. PubMed ID: 27203278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lurasidone: a new treatment option for schizophrenia.
    Owen RT
    Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
    Corponi F; Fabbri C; Bitter I; Montgomery S; Vieta E; Kasper S; Pallanti S; Serretti A
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):971-985. PubMed ID: 31255396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone-Induced Dystonia.
    Tibrewal P; Cheng R; Bastiampillai T; Dhillon R; Okungu A; Campbell J
    Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28682525
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis.
    Ng-Mak D; Tongbram V; Ndirangu K; Rajagopalan K; Loebel A
    J Comp Eff Res; 2018 Aug; 7(8):737-748. PubMed ID: 29697278
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.
    Higuchi T; Iyo M; Kwon JS; Chou YH; Chen HK; Chen JY; Chen TT; Huang SY; Lee JS; Saeki Y; Tanaka H; Wang TS; Wu BJ; Katoh T; Ishigouoka J
    Asia Pac Psychiatry; 2019 Sep; 11(3):e12354. PubMed ID: 30912222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
    Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
    Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.
    Greenberg WM; Citrome L
    Clin Pharmacokinet; 2017 May; 56(5):493-503. PubMed ID: 27722855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.
    Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT
    J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Ben Gharbia M; Garnier M; Llorca PM
    Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.